Market Opportunity

$20 BILLION/YEAR

In the US, there are 170,000 people who have low Th2 asthma

Annual cost of current standard of care branded agent ~$25,000 year

Therefore, the total U.S. market opportunity for LGM2605 in low Th2 asthma is ~$4.25 Billion per year


In the US, there are 160,000 Pulmonary Fibrosis patients

Annual cost of current standard of care branded agent ~$100,000 year

Therefore, the total U.S. market opportunity for LGM2605 is ~$16 Billion per year